SiBone (NASDAQ:SIBN) Shares Gap Up – What’s Next?

SiBone (NASDAQ:SIBN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $15.68, but opened at $16.77. SiBone shares last traded at $18.4820, with a volume of 376,206 shares.

Wall Street Analyst Weigh In

A number of research firms recently commented on SIBN. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Truist Financial decreased their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Stock Performance

The business has a 50 day moving average price of $15.21 and a 200 day moving average price of $16.56. The stock has a market capitalization of $822.29 million, a PE ratio of -34.04 and a beta of 0.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,833 shares of SiBone stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total value of $59,871.46. Following the completion of the sale, the insider directly owned 275,288 shares in the company, valued at approximately $4,299,998.56. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura Francis sold 11,343 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.60, for a total transaction of $176,950.80. Following the transaction, the chief executive officer owned 419,704 shares in the company, valued at $6,547,382.40. This represents a 2.63% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 32,009 shares of company stock valued at $485,884. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SiBone

Several large investors have recently added to or reduced their stakes in SIBN. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone during the 1st quarter worth $34,000. State of Alaska Department of Revenue purchased a new position in SiBone during the third quarter valued at $39,000. State of Wyoming bought a new stake in SiBone during the second quarter valued at about $55,000. Virtus Advisers LLC purchased a new stake in SiBone in the first quarter worth about $58,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of SiBone in the second quarter worth about $68,000. 98.11% of the stock is currently owned by institutional investors.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.